title: Reply to Drs. Olanow and Rascol.
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. eahlskog@mayo.edu
authors.forename: J Eric
authors.initials: JE
authors.lastname: Ahlskog
authors.forename: Ryan J
authors.initials: RJ
authors.lastname: Uitti
mesh_terms: D015415:Biomarkers / Q000032:analysis; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards*; D003627:Data Interpretation, Statistical; D006801:Humans; D007189:Indans / Q000008:administration & dosage*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000592:standards*; D010300:Parkinson Disease / Q000188:drug therapy*; D015990:Placebo Effect; D015203:Reproducibility of Results; D012107:Research Design / Q000592:standards*
chemical_list: D015415:Biomarkers; D007189:Indans; D018696:Neuroprotective Agents; C031967:rasagiline